{
    "organizations": [],
    "uuid": "ee5320701e6e641df390aa1ead0cfac170fb71f9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-valneva-total-revenues-up-at-1098/brief-valneva-total-revenues-up-at-109-8-million-euros-idUSFWN1Q508U",
    "ord_in_thread": 0,
    "title": "BRIEF-Valneva ‍Total Revenues Up At 109.8 Million Euros",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 15 (Reuters) - VALNEVA SE:\n* ‍TOTAL REVENUES OF EUR 109.8 MILLION IN 2017 (2016 - EUR 97.9 MILLION)​\n* ‍PRODUCT SALES OF EUR 92.6 MILLION IN 2017 (2016 - EUR 80.4 MILLION)​\n* ‍CASH POSITION OF EUR 38.1 MILLION AT END OF 2017​ * ‍VALNEVA EXPECTS TO ANNOUNCE PHASE I TOP-LINE DATA FOR ITS LYME DISEASE VACCINE CANDIDATE IN Q1 OF 2018​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-15T14:09:00.000+02:00",
    "crawled": "2018-02-16T17:12:18.018+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "valneva",
        "se",
        "revenue",
        "eur",
        "million",
        "eur",
        "million",
        "sale",
        "eur",
        "million",
        "eur",
        "million",
        "position",
        "eur",
        "million",
        "end",
        "expects",
        "announce",
        "phase",
        "data",
        "lyme",
        "disease",
        "vaccine",
        "candidate",
        "q1",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}